<DOC>
	<DOCNO>NCT00812864</DOCNO>
	<brief_summary>The aim study determine blood concentration evolution capecitabine active metabolite , elderly patient 75 year .</brief_summary>
	<brief_title>Pharmacokinetic Study Capecitabine Elderly Cancer Patient ( ≥ 75 Years )</brief_title>
	<detailed_description>Blood sample take 1rst course chemotherapy capécitabine colorectal breast metastatic cancer . Pharmacokinetic realize several time ( H0,5 , H1 , H1,5 , H2 , H4 , H6 , H8 ) repeat D14 2d cycle</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Elderly patient 75 year old Life expectancy great equal 6 month Histologically proven metastatic breast colorectal cancer , require chemotherapy capecitabine accord habitual schema Metastatic situation whatever treatment line Previous hormonotherapy breast cancer , prior chemotherapy ( without capecitabine ) adjuvant and/or metastatic indication ( colorectal breast cancer ) , radiotherapy ( colorectal breast cancer ) allow One measurable target lesion ( RECIST criterion ) ADL &gt; 4 ( geriatric scale ) GSD &lt; 12 ( geriatric scale ) Laboratory value : creatinine clearance ( CrCl ) &gt; =30 mL/min accord Cockcroft formula Adequate bone marrow function ( neutrophils count &gt; 1.5 x 10^9/L , platelet &gt; 100 x 10^9/L , hemoglobin [ Hb ] &gt; 10g/dl ) Adequate hepatic function : total bilirubin &lt; 1,5 x upper normal limit , aspartate aminotransferase ( ASAT ) alanine aminotransferase ( ALAT ) &lt; 2,5x upper normal limit ( case liver metastases &lt; 5 x upper normal limit ) Alcalin phosphatase &lt; =2,5x ULN ( &lt; =5 x ULN liver metastasis present ) . Subjects must willing follow course treatment/observation followup . Signed write informed consent first course chemotheray Age &lt; 75 year know brain metastasis Concomitant oncologic treatment ongoing History severe unscheduled reaction fluoropyrimidine treatment Prior unanticipated severe reaction capecitabine metabolites fluoropyrimidine therapy Patient leucopenia sorivudine chemical analogue treatment like brivudine Physiological , familial , sociological , geographical condition permit compliance protocol . Concomitant severe affection wich lead life expectancy inferior 3 monthes Uncontrolled symptomatic angina , arrhythmia , congestive heart failure , coronarian spasmes No possible oral administration know DPD deficiency Treatment experimental therapy ongoing within four week inclusion . Other cancer within last five year , exception adequately treat conebiopsied situ carcinoma uterin cervix basal squamous cell carcinoma skin</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Capecitabine</keyword>
	<keyword>pharmacocinetics</keyword>
	<keyword>Breast metastatic cancer</keyword>
	<keyword>colorectal metastatic cancer</keyword>
	<keyword>Elderly patient</keyword>
</DOC>